Glenmark arm inks licensing pact with Astria Therapeutics
Glenmark Pharma news: With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the company's prioritisation of its pipeline of oncology drug candidates, Ichnos Sciences said in a statement filed on BSE by Glenmark.
Glenmark Pharmaceuticals Ltd on Thursday said its wholly-owned arm Ichnos Sciences has signed an exclusive worldwide licensing agreement with Astria Therapeutics. Image: Official website/ Representational image